{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:06:43Z","timestamp":1788476803442,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KO2155\/6-1"],"award-info":[{"award-number":["KO2155\/6-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"START grant, Faculty of Medicine, RWTH Aachen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1038\/s41375-019-0629-z","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T14:02:38Z","timestamp":1573740158000},"page":"1062-1074","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms"],"prefix":"10.1038","volume":"34","author":[{"given":"Julian","family":"Baumeister","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4485-3120","authenticated-orcid":false,"given":"Nicolas","family":"Chatain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Hubrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Mai\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2890-8697","authenticated-orcid":false,"given":"Ivan G.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Denecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"K\u00fcstermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Sontag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Ser\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Strathmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schuppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil R.","family":"Kranc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1011-8171","authenticated-orcid":false,"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Gezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"issue":"2 Suppl 3","key":"629_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/j.seminhematol.2004.02.011","volume":"41","author":"JL Spivak","year":"2004","unstructured":"Spivak JL. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol. 2004;41 2 Suppl 3:1\u20135.","journal-title":"Semin Hematol"},{"key":"629_CR2","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779\u201390.","journal-title":"N Engl J Med"},{"key":"629_CR3","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.","journal-title":"PLoS Med"},{"key":"629_CR4","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379\u201390.","journal-title":"N Engl J Med"},{"key":"629_CR5","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMc051878","volume":"353","author":"A Tefferi","year":"2005","unstructured":"Tefferi A, Lasho TL, Gilliland G. JAK2 mutations in myeloproliferative disorders. N Engl J Med. 2005;353:1416\u20137. author reply 1416\u20137.","journal-title":"N Engl J Med"},{"key":"629_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1182\/blood-2017-04-742288","volume":"130","author":"P Bose","year":"2017","unstructured":"Bose P, Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood. 2017;130:115\u201325.","journal-title":"Blood"},{"key":"629_CR7","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","volume":"4","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017;4:e225\u201336.","journal-title":"Lancet Haematol"},{"key":"629_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.12688\/f1000research.13167.1","volume":"7","author":"W Vainchenker","year":"2018","unstructured":"Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Res. 2018;7:82.","journal-title":"F1000Res"},{"key":"629_CR9","doi-asserted-by":"publisher","first-page":"e0179545","DOI":"10.1371\/journal.pone.0179545","volume":"12","author":"AM Graham","year":"2017","unstructured":"Graham AM, Presnell JS. Hypoxia Inducible Factor (HIF) transcription factor family expansion, diversification, divergence and selection in eukaryotes. PLoS ONE. 2017;12:e0179545.","journal-title":"PLoS ONE"},{"key":"629_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","volume":"30","author":"WG Kaelin Jr.","year":"2008","unstructured":"Kaelin WG Jr., Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30:393\u2013402.","journal-title":"Mol Cell"},{"key":"629_CR11","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/stem.1657","volume":"32","author":"D Gezer","year":"2014","unstructured":"Gezer D, Vukovic M, Soga T, Pollard PJ, Kranc KR. Concise review: genetic dissection of hypoxia signaling pathways in normal and leukemic stem cells. Stem Cells. 2014;32:1390\u20137.","journal-title":"Stem Cells"},{"key":"629_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/ncb2730","volume":"15","author":"C Nombela-Arrieta","year":"2013","unstructured":"Nombela-Arrieta C, Pivarnik G, Winkel B, Canty KJ, Mahoney JE, Park S-Y, et al. Quantitative imaging of hematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment. Nat Cell Biol. 2013;15:533\u201343.","journal-title":"Nat Cell Biol"},{"key":"629_CR13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.stem.2010.06.020","volume":"7","author":"K Takubo","year":"2010","unstructured":"Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y, et al. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell. 2010;7:391\u2013402.","journal-title":"Cell Stem Cell"},{"key":"629_CR14","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1182\/blood-2015-10-677138","volume":"127","author":"M Vukovic","year":"2016","unstructured":"Vukovic M, Sepulveda C, Subramani C, Guitart AV, Mohr J, Allen L, et al. Adult hematopoietic stem cells lacking Hif-1alpha self-renew normally. Blood. 2016;127:2841\u20136.","journal-title":"Blood"},{"key":"629_CR15","doi-asserted-by":"crossref","unstructured":"Guitart AV, Subramani C, Armesilla-Diaz A, Smith G, Sepulveda C, Gezer D, et al. Hif-2\u03b1 is not essential for cell-autonomous hematopoietic stem cell maintenance. Blood. 2013;122:1741\u20135.","DOI":"10.1182\/blood-2013-02-484923"},{"key":"629_CR16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.20892\/j.issn.2095-3941.2016.0023","volume":"13","author":"H-S Zhou","year":"2016","unstructured":"Zhou H-S, Carter BZ, Andreeff M. Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang. Cancer Biol Med. 2016;13:248\u201359.","journal-title":"Cancer Biol Med"},{"key":"629_CR17","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/sj.leu.2403332","volume":"18","author":"S Wellmann","year":"2004","unstructured":"Wellmann S, Guschmann M, Griethe W, Eckert C, Stackelberg A, Lottaz C, et al. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia. 2004;18:926\u201333.","journal-title":"Leukemia"},{"key":"629_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.stem.2011.02.006","volume":"8","author":"Y Wang","year":"2011","unstructured":"Wang Y, Liu Y, Malek SN, Zheng P, Liu Y. Targeting HIF1\u03b1 eliminates cancer stem cells in hematological malignancies. Cell Stem Cell. 2011;8:399\u2013411.","journal-title":"Cell Stem Cell"},{"key":"629_CR19","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1182\/blood-2011-10-387381","volume":"119","author":"H Zhang","year":"2012","unstructured":"Zhang H, Li H, Xi HS, Li S. HIF1\u03b1 is required for survival maintenance of chronic myeloid leukemia stem cells. Blood. 2012;119:2595\u2013607.","journal-title":"Blood"},{"key":"629_CR20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/ng1019","volume":"32","author":"SO Ang","year":"2002","unstructured":"Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002;32:614\u201321.","journal-title":"Nat Genet"},{"key":"629_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMoa073123","volume":"358","author":"MJ Percy","year":"2008","unstructured":"Percy MJ, Furlow PW, Lucas GS, Li X, Lappin TR, McMullin MF, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med. 2008;358:162\u20138.","journal-title":"N Engl J Med"},{"key":"629_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/HP.S54455","volume":"2","author":"B Gardie","year":"2014","unstructured":"Gardie B, Percy MJ, Hoogewijs D, Chowdhury R, Bento C, Arsenault PR, et al. The role of PHD2 mutations in the pathogenesis of erythrocytosis. Hypoxia. 2014;2:71\u201390.","journal-title":"Hypoxia"},{"key":"629_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0135463","volume":"10","author":"VP \u010coki\u0107","year":"2015","unstructured":"\u010coki\u0107 VP, Mossuz P, Han J, Socoro N, Beleslin-\u010coki\u0107 BB, Mitrovi\u0107 O, et al. Microarray and proteomic analyses of myeloproliferative neoplasms with a highlight on the mTOR signaling pathway. PLoS ONE. 2015;10:1\u201323.","journal-title":"PLoS ONE"},{"key":"629_CR24","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1074\/jbc.M806653200","volume":"284","author":"H Harada","year":"2009","unstructured":"Harada H, Itasaka S, Kizaka-Kondoh S, Shibuya K, Morinibu A, Shinomiya K, et al. The Akt\/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J Biol Chem. 2009;284:5332\u201342.","journal-title":"J Biol Chem"},{"key":"629_CR25","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/leu.2013.102","volume":"27","author":"C Marty","year":"2013","unstructured":"Marty C, Lacout C, Droin N, Le Cou\u00e9dic JP, Ribrag V, Solary E, et al. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia. 2013;27:2187\u201395.","journal-title":"Leukemia"},{"key":"629_CR26","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.exphem.2010.07.005","volume":"38","author":"C Vener","year":"2010","unstructured":"Vener C, Novembrino C, Bamonti Catena F, Fracchiolla NS, Gianelli U, Savi F, et al. Oxidative stress is increased in primary and post-polycythemia vera myelofibrosis. Exp Hematol. 2010;38:1058\u201365.","journal-title":"Exp Hematol"},{"key":"629_CR27","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/carcin\/bgn032","volume":"29","author":"SN Jung","year":"2008","unstructured":"Jung SN, Yang WK, Kim J, Kim HS, Kim EJ, Yun H, et al. Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells. Carcinogenesis. 2008;29:713\u201321.","journal-title":"Carcinogenesis"},{"key":"629_CR28","first-page":"669","volume":"47","author":"Q Xu","year":"2016","unstructured":"Xu Q, Liu GM, Wang FY, Zhang LJ, Liang WT, Cheng ZY. The effect of ruxolitinib on the expression of VEGF and HIF-1 alpha in leukemia HEL cells. Sichuan Da Xue Xue Bao Yi Xue Ban. 2016;47:669\u201373.","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"629_CR29","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.exphem.2014.05.007","volume":"42","author":"T Mitsumori","year":"2014","unstructured":"Mitsumori T, Nozaki Y, Kawashima I, Yamamoto T, Shobu Y, Nakajima K, et al. Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells. Exp Hematol. 2014;42:783\u201392 e781.","journal-title":"Exp Hematol"},{"key":"629_CR30","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.cell.2004.08.025","volume":"118","author":"D Gerald","year":"2004","unstructured":"Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, et al. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell. 2004;118:781\u201394.","journal-title":"Cell"},{"key":"629_CR31","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098\u2013107.","journal-title":"N Engl J Med"},{"key":"629_CR32","doi-asserted-by":"crossref","first-page":"7625","DOI":"10.18632\/oncotarget.13825","volume":"8","author":"J Zhang","year":"2017","unstructured":"Zhang J, Su L, Ye Q, Zhang S, Kung H, Jiang F, et al. Discovery of a novel Nrf2 inhibitor that induces apoptosis of human acute myeloid leukemia cells. Oncotarget. 2017;8:7625\u201336.","journal-title":"Oncotarget"},{"key":"629_CR33","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/jcmm.13367","volume":"22","author":"Y Yamaguchi","year":"2018","unstructured":"Yamaguchi Y, Kanzaki H, Katsumata Y, Itohiya K, Fukaya S, Miyamoto Y, et al. Dimethyl fumarate inhibits osteoclasts via attenuation of reactive oxygen species signalling by augmented antioxidation. J Cell Mol Med. 2018;22:1138\u201347.","journal-title":"J Cell Mol Med"},{"key":"629_CR34","doi-asserted-by":"publisher","first-page":"9047","DOI":"10.1158\/0008-5472.CAN-05-1235","volume":"65","author":"D Kong","year":"2005","unstructured":"Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A, et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 2005;65:9047\u201355.","journal-title":"Cancer Res"},{"key":"629_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.bjhh.2016.04.009","volume":"38","author":"JA Machado-Neto","year":"2016","unstructured":"Machado-Neto JA, Traina F. Reactive oxygen species overload promotes apoptosis in JAK2V617F-positive cell lines. Rev Bras Hematol Hemoter. 2016;38:179\u201381.","journal-title":"Rev Bras Hematol Hemoter"},{"key":"629_CR36","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/onc.2015.285","volume":"35","author":"JS Ahn","year":"2016","unstructured":"Ahn JS, Li J, Chen E, Kent DG, Park HJ, Green aR. JAK2V617F mediates resistance to DNA damage-induced apoptosis by modulating FOXO3A localization and Bcl-xL deamidation. Oncogene. 2016;35:2235\u201346.","journal-title":"Oncogene"},{"key":"629_CR37","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ccr.2010.10.013","volume":"18","author":"E Chen","year":"2010","unstructured":"Chen E, Beer PA, Godfrey AL, Ortmann CA, Li J, Costa-Pereira AP, et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell. 2010;18:524\u201335.","journal-title":"Cancer Cell"},{"key":"629_CR38","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1365-2141.2010.08249.x","volume":"150","author":"S Oku","year":"2010","unstructured":"Oku S, Takenaka K, Kuriyama T, Shide K, Kumano T, Kikushige Y, et al. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation. Br J Haematol. 2010;150:334\u201344.","journal-title":"Br J Haematol"},{"key":"629_CR39","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/hep.23597","volume":"51","author":"H Menrad","year":"2010","unstructured":"Menrad H, Werno C, Schmid T, Copanaki E, Deller T, Dehne N, et al. Roles of hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1) versus HIF-2\u03b1 in the survival of hepatocellular tumor spheroids. Hepatology. 2010;51:2183\u201392.","journal-title":"Hepatology"},{"key":"629_CR40","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.febslet.2012.04.039","volume":"586","author":"K Schulz","year":"2012","unstructured":"Schulz K, Milke L, R\u00fcbsamen D, Menrad H, Schmid T, Br\u00fcne B. HIF-1\u03b1 protein is upregulated in HIF-2\u03b1 depleted cells via enhanced translation. FEBS Lett. 2012;586:1652\u20137.","journal-title":"FEBS Lett"},{"key":"629_CR41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nchembio.1185","volume":"9","author":"TH Scheuermann","year":"2013","unstructured":"Scheuermann TH, Li Q, Ma H-W, Key J, Zhang L, Chen R, et al. Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat Chem Biol. 2013;9:271\u20136.","journal-title":"Nat Chem Biol"},{"key":"629_CR42","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.15252\/embr.201643030","volume":"17","author":"R Nagel","year":"2016","unstructured":"Nagel R, Semenova EA, Berns A. Drugging the addict: non-oncogene addiction as a target for cancer therapy. EMBO Rep. 2016;17:1516\u201331.","journal-title":"EMBO Rep"},{"key":"629_CR43","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.tips.2015.03.003","volume":"36","author":"G Peng","year":"2015","unstructured":"Peng G, Liu Y. Hypoxia-inducible factors in cancer stem cells and inflammation. Trends Pharmacol Sci. 2015;36:374\u201383.","journal-title":"Trends Pharmacol Sci"},{"key":"629_CR44","doi-asserted-by":"crossref","first-page":"62793","DOI":"10.18632\/oncotarget.19513","volume":"8","author":"L Lu","year":"2017","unstructured":"Lu L, Chen Y, Zhu Y. The molecular basis of targeting PFKFB3 as a therapeutic strategy against cancer. Oncotarget. 2017;8:62793\u2013802.","journal-title":"Oncotarget"},{"key":"629_CR45","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/0959-437X(94)90098-1","volume":"4","author":"B Amati","year":"1994","unstructured":"Amati B, Land H. Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death. Curr Opin Genet Dev. 1994;4:102\u20138.","journal-title":"Curr Opin Genet Dev"},{"key":"629_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18844-3","volume":"8","author":"A Ruiz","year":"2018","unstructured":"Ruiz A, Dror E, Handschin C, Furrer R, Perez-Schindler J, Bachmann C, et al. Over-expression of a retinol dehydrogenase (SRP35\/DHRS7C) in skeletal muscle activates mTORC2, enhances glucose metabolism and muscle performance. Sci Rep. 2018;8:636.","journal-title":"Sci Rep"},{"key":"629_CR47","doi-asserted-by":"publisher","first-page":"e0116740","DOI":"10.1371\/journal.pone.0116740","volume":"10","author":"P Kucharzewska","year":"2015","unstructured":"Kucharzewska P, Christianson HC, Belting M. Global profiling of metabolic adaptation to hypoxic stress in human glioblastoma cells. PLoS ONE. 2015;10:e0116740.","journal-title":"PLoS ONE"},{"key":"629_CR48","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fonc.2017.00286","volume":"7","author":"L Iommarini","year":"2017","unstructured":"Iommarini L, Porcelli AM, Gasparre G, Kurelac I. Non-canonical mechanisms regulating hypoxia-inducible factor 1 alpha in cancer. Front Oncol. 2017;7:286.","journal-title":"Front Oncol"},{"key":"629_CR49","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","volume":"5","author":"GN Masoud","year":"2015","unstructured":"Masoud GN, Li W. HIF-1?? pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5:378\u201389.","journal-title":"Acta Pharm Sin B"},{"key":"629_CR50","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","volume":"116","author":"C Marty","year":"2010","unstructured":"Marty C, Lacout C, Martin A, Hasan S, Jacquot S, Birling MC, et al. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood. 2010;116:783\u20137.","journal-title":"Blood"},{"key":"629_CR51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","volume":"148","author":"GL Semenza","year":"2012","unstructured":"Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148:399\u2013408.","journal-title":"Cell"},{"key":"629_CR52","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.3892\/ol.2015.3545","volume":"10","author":"N Abd-Aziz","year":"2015","unstructured":"Abd-Aziz N, Stanbridge EJ, Shafee N. Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation. Oncol Lett. 2015;10:2192\u20136.","journal-title":"Oncol Lett"},{"key":"629_CR53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11255-008-9460-6","volume":"41","author":"AI Dokucu","year":"2009","unstructured":"Dokucu AI, Ozturk H, Ozturk H, Tuncer MC, Yilmaz F. The effects of molsidomine on hypoxia inducible factor alpha and Sonic hedgehog in testicular ischemia\/reperfusion injury in rats. Int Urol Nephrol. 2009;41:101\u20138.","journal-title":"Int Urol Nephrol"},{"key":"629_CR54","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1182\/blood-2013-12-544221","volume":"124","author":"Y Wang","year":"2014","unstructured":"Wang Y, Liu Y, Tang F, Bernot KM, Schore R, Marcucci G, et al. Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells. Blood. 2014;124:1127\u201335.","journal-title":"Blood"},{"key":"629_CR55","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.4161\/cc.9.19.13160","volume":"9","author":"VS Romanov","year":"2010","unstructured":"Romanov VS, Abramova MV, Svetlikova SB, Bykova TV, Zubova SG, Aksenov ND, et al. p21(Waf1) is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate. Cell Cycle. 2010;9:3945\u201355.","journal-title":"Cell Cycle"},{"key":"629_CR56","first-page":"1521","volume":"9","author":"B Lv","year":"2017","unstructured":"Lv B, Li F, Fang J, Xu L, Sun C, Han J, et al. Hypoxia inducible factor 1alpha promotes survival of mesenchymal stem cells under hypoxia. Am J Transl Res. 2017;9:1521\u20139.","journal-title":"Am J Transl Res"},{"key":"629_CR57","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.molcel.2011.10.015","volume":"44","author":"T Hitosugi","year":"2011","unstructured":"Hitosugi T, Fan J, Chung TW, Lythgoe K, Wang X, Xie J, et al. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell. 2011;44:864\u201377.","journal-title":"Mol Cell"},{"key":"629_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0024-9","volume":"7","author":"S Shah","year":"2017","unstructured":"Shah S, Mudireddy M, Hanson CA, Ketterling RP, Gangat N, Pardanani A, et al. Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates. Blood Cancer J. 2017;7:657.","journal-title":"Blood Cancer J"},{"key":"629_CR59","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/leu.2011.225","volume":"26","author":"MM Reddy","year":"2012","unstructured":"Reddy MM, Fernandes MS, Deshpande A, Weisberg E, Inguilizian HV, Abdel-Wahab O, et al. The JAK2V617F oncogene requires expression of inducible phosphofructokinase\/fructose-bisphosphatase 3 for cell growth and increased metabolic activity. Leukemia. 2012;26:481\u20139.","journal-title":"Leukemia"},{"key":"629_CR60","doi-asserted-by":"publisher","unstructured":"Nageswara Rao T, Hansen N, Hilfiker J, Rai S, Majewska JM, Lekovic D, et al. JAK2 mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood. 2019. https:\/\/doi.org\/10.1182\/blood.2019000162.","DOI":"10.1182\/blood.2019000162"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0629-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0629-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0629-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T22:40:18Z","timestamp":1722033618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0629-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["629"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0629-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,14]]},"assertion":[{"value":"17 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SK reports advisory board activity for Pfizer, Incyte\/Ariad, Novartis, AOP Pharma, BMS, CTI, Roche, Baxalta, Sanofi, honoraria from Novartis, BMS, Pfizer, Incyte\/Ariad, Shire, Roche, AOP Pharma, Janssen, research funding from Novartis Foundation, BMS, Novartis, and other financial disclosures (i.e., travel support) from Alexion, Novartis, BMS, Incyte\/Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, and Janssen. THB reports consultancy from Pfizer, Novartis, Janssen, Merck, Incyte\/Ariad and research funding from Pfizer and Novartis. DG reports advisory board activity for AMGEN. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}